TNFSF13B and arthritic joint disease: Anti-BLyS/BAFF therapy, belimumab, seems to improve arthritis manifestations in pSS patients [92], while ianalumab (VAY736), another B cell-depleting BAFF-R blocker, provided promising results in recent studies [93].